Join the Non-Small Cell Lung Cancer group to help and get support from people like you.
Non-Small Cell Lung Cancer News (Page 2)
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...
FDA Approves Ensacove (ensartinib) for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or...
Are Microplastics In the Air Putting Your Fertility At Risk?
WEDNESDAY, Dec. 18, 2024 – Microscopic plastic particles in the air could be contributing to a wide variety of health problems, including lung and colon cancers. Tires and degrading garbage shed...
Metformin Beneficial in Lung Cancer Patients With Overweight, Obesity
TUESDAY, Dec. 10, 2024 – In non-small cell lung cancer (NSCLC) patients with overweight or obesity, metformin may improve lung cancer-specific clinical outcomes, according to a study published...
FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) – Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative,...
American Lung Association Releases Annual 'State of Lung Cancer' Report
MONDAY, Dec. 2, 2024 – The lung cancer survival rate improved 26 percent in the last five years, according to the "State of Lung Cancer" report published by the American Lung Association. The annual...
Smoker or Former Smoker? Here Are 4 Key Things You Need to Know
MONDAY, Dec.2, 2024 — Doctors have potent new weapons against the deadliest cancer in America and they want to make sure they're on the radar of current and former smokers. "Lung cancer screening is t...
Diabetes Drug Metformin Might Help Fight Lung Cancer
WEDNESDAY, Nov. 27, 2024 – Already the go-to drug of choice for millions with type 2 diabetes, metformin might also fight lung cancer if those patients have it as well, new research shows. Metformin...
There's Been a Big Improvement in Lung Cancer Survival
TUESDAY, Nov. 19, 2024 – More people with lung cancer are living longer, but it remains America's deadliest cancer, a new state-by-state report shows. "There is more work to do, but I am incredibly...
Few High-Risk Individuals Have Heard of, Discuss Lung Cancer Screening
TUESDAY, Nov. 12, 2024 – Few high-risk individuals have heard of or have discussed lung cancer screening (LCS) with a health care practitioner, according to a research letter published online Oct....
Early Steps to a Breath Test for Lung Cancer
THURSDAY, Nov. 7, 2024 – An experimental portable device might be able to detect lung cancer from a person’s exhaled breath, researchers report. The device contains “nanoflake” sensors that can detec...
Tobacco-Free Generation Could Prevent 40 Percent of Predicted Lung Cancer Deaths Globally
MONDAY, Oct. 7, 2024 – Implementation of a tobacco-free generation could substantially reduce global lung cancer mortality, according to a study published in the October issue of The Lancet Public ...
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE) Oct 03, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo ® (nivolumab) for the treatment of ...
Rybrevant (amivantamab-vmjw) Plus Standard of Care Approved in the U.S. as First and Only Targeted Regimen to Cut Risk of Disease Progression by More Than Half in Second-Line EGFR-Mutated Advanced Lung Cancer
RARITAN, New Jersey (September 19, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) in combination with s...
FDA Approves Rybrevant (amivantamab-vmjw) Plus Lazcluze (lazertinib) for Patients with EGFR-Mutated Advanced Lung cancer
RARITAN, N.J., Aug. 20, 2024 /PRNewswire/ – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Rybrevant® (amivantamab-vmjw) plus Lazcluze™ (l...